Drug intelligence / Profile preview

apixaban + edoxaban + rivaroxaban

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of three direct oral anticoagulants (DOACs) that selectively inhibit factor Xa in the coagulation cascade. All three drugs prevent thrombus formation by inhibiting factor Xa and prothrombinase, thereby preventing the conversion of prothrombin into thrombin. These medications are used for preventing stroke in non-valvular atrial fibrillation and for treating and preventing venous thromboembolism.

Brand names: Eliquis + Savaysa/Lixiana + Xarelto

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on apixaban + edoxaban + rivaroxaban.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on apixaban + edoxaban + rivaroxaban.

Explore the full profile